Search
Search
Who we are
Overview: about the EBRDWho we are
Overview: about the EBRD
Our story
Learn about the EBRD's journey to investing more than €220 billion in over 7,800 projects.
- Our background and history
- Our organisation
- Our values
- Strategies, governance and compliance
- Project accountability
What we do
Overview: how the EBRD operatesWhat we do
Overview: how the EBRD operates
How we deliver systemic impact
Across three continents, the EBRD supports the transition to successful market economies.
- Where we work
- Products and services
- Sectors we work in
- Our projects
- Focus areas and initiatives
- Economic research
Work with us
Overview: how you can work with the EBRDWork with us
Overview: how you can work with the EBRD
What we offer for businesses
We draw on three decades of regional knowledge and financial expertise to tailor our products and approaches to each client's needs.
- Businesses
- Investors
- Donors
- Researchers
- Civil Society
- Alumni
- Nominee Directors
- Trade finance
- Careers
Light
Eng
Eng
- EBRD providing a loan of up to US$ 25 million to Meros Pharm
- Funds will finance working capital needs of major pharmaceutical distributor
- Company is planning to expand its network of warehouses
The European Bank for Reconstruction and Development (EBRD) is promoting competition and transparency in Uzbekistan’s pharmaceutical sector by supporting the operations of its client Meros Pharm.
The EBRD’s senior loan of up to US$ 25 million (€21.9 million) will help the country’s second largest wholesale distributor of pharmaceutical products to finance working capital needs associated with the planned regional expansion of its warehouse network. The funds will also allow Meros Pharm to better manage its stocks before and during periods of peak demand.
The expansion of the privately owned and fully compliant distributor will increase competition in the sector. It will help to address logistical challenges, improve the company’s operational performance, and shorten delivery times, giving customers across Uzbekistan improved access to high-quality, affordable medication.
Meros Pharm will also implement improvements in corporate governance supported by the EBRD.
This project will set new standards in the distribution of pharmaceutical products and support the government’s efforts to strengthen regulation and increase transparency in the sector.
The project was supported by technical cooperation funds provided by Japan-EBRD Cooperation Fund to partially cover legal due diligence cost.
The Bank has invested almost €5.6 billion in Uzbekistan to date across 181 projects, with most of the funds supporting private entrepreneurship. The country has been the leading recipient of EBRD funding in Central Asia for each of the past five years.